R-6600 Ruxolitinib, Free Base, >99%

Synonyms : [INCB018424] [INCB18424] [NCB018424] [NCB18424]

Related Terms : [Jakafi]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 41
  • 37
  • 31
  • 4,600
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 54
  • 49
  • 41
  • 6,000
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 79
  • 72
  • 61
  • 8,800
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 106
  • 97
  • 81
  • 11,800
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 176
  • 161
  • 136
  • 19,600
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 313
  • 287
  • 241
  • 34,800
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 369
  • 338
  • 285
  • 41,100
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 622
  • 570
  • 480
  • 69,200
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 988
  • 906
  • 763
  • 110,000
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 306.37
  • C17H18N6
  • [941678-49-5]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 28 mg/mL; soluble in ethanol at 15 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • This is the free base form of ruxolitinib, also known as INCB18424; please see the other form of this product, Ruxolitinib, Phosphate Salt, Cat. No. R-6688, for further technical information. The phosphate salt form of ruxolitinib is used for some or all ruxolitinib formulations for use in humans.
  • Ruxolitinib (as the phosphate salt) is the active ingredient in the drug sold under the trade name Jakafi® by Incyte Corporation. Jakafi® is currently approved in at least one country for use in patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. NOTE: THE RUXOLITINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT JAKAFI® AND IS NOT FOR HUMAN USE. Jakafi® is a registered trademark of Incyte Corporation. LC Laboratories is not affiliated with Incyte Corporation, and the ruxolitinib research compounds sold by LC Laboratories are not manufactured by Incyte Corporation.
  • This ruxolitinib product research compound is the free base, whose CAS number is given above. The CAS number of the phosphate salt is 1092939-17-7.
  • As of September 2011, it appears that Chemical Abstracts Service currently also has a second CAS number for Ruxolitinib, Free Base, namely 1160597-27-2.
  • Another CAS number previously assigned to Ruxolitinib, Free Base, namely 1138325-12-8, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
269